Follow
"Briefing documents released 27 October suggest that FDA examiners have zeroed in on this possibility, and it is slated to become a key discussion point when advisors meet to discuss the risks and benefits of exa-cel next week.
In particular, the FDA flagged two potential shortcomings in assays that Vertex and CRISPR Therapeutics used to determine exa-cel’s risk of causing off-target changes"
